Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its product ALTO-100 and its business prospects [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto common stock during the IPO on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made materially false and misleading statements about Alto's business and operations [5]. - Specific claims include that ALTO-100 was less effective in treating major depressive disorder than represented, leading to overstated clinical and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit